Yeonhee Park1, Heather J Fullerton2, Jordan J Elm3. 1. Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, United States. 2. Departments of Neurology & Pediatrics, University of California, San Francisco, San Francisco, CA, United States. 3. Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, United States. Electronic address: elmj@musc.edu.
Abstract
BACKGROUND: Pediatric stroke investigators identified as their top research priority a clinical trial of corticosteroids for focal cerebral arteriopathy (FCA). However, FCA is both rare and an acute condition making it infeasible to enroll the large sample sizes needed for standard, confirmatory clinical trials. We present a pragmatic approach to clinical trial design that may inform the approach to other rare disorders. METHODS: We surveyed pediatric stroke experts to determine the level of evidence that would impact their clinical management of FCA. Incorporating survey results, a randomized, group sequential Bayesian adaptive design was proposed based on a quantitative radiologic outcome measure (change from baseline in change in the FCA Severity Score). Using accumulating information, the design determines whether intervention is better than control with high probability. RESULTS: Among 21 (100%) respondents, the probability of corticosteroid efficacy that would lead the experts to treat was 30% (median). The probability of efficacy that would make them unwilling to randomize (because they would feel all children should receive corticosteroids) was 70%. Simulation studies with the proposed design showed that a total of 42 subjects controls the type I error rate at the desired level 0.20 and yields a smaller average sample size and trial duration compared to a conventional design. CONCLUSIONS: Designs in rare diseases require special considerations; this is especially true for this childhood disease, which is both uncommon and acute. This design has incorporated expert consensus to establish the criteria for success, formal monitoring rules for safety, and early stopping rules.
RCT Entities:
BACKGROUND: Pediatric stroke investigators identified as their top research priority a clinical trial of corticosteroids for focal cerebral arteriopathy (FCA). However, FCA is both rare and an acute condition making it infeasible to enroll the large sample sizes needed for standard, confirmatory clinical trials. We present a pragmatic approach to clinical trial design that may inform the approach to other rare disorders. METHODS: We surveyed pediatric stroke experts to determine the level of evidence that would impact their clinical management of FCA. Incorporating survey results, a randomized, group sequential Bayesian adaptive design was proposed based on a quantitative radiologic outcome measure (change from baseline in change in the FCA Severity Score). Using accumulating information, the design determines whether intervention is better than control with high probability. RESULTS: Among 21 (100%) respondents, the probability of corticosteroid efficacy that would lead the experts to treat was 30% (median). The probability of efficacy that would make them unwilling to randomize (because they would feel all children should receive corticosteroids) was 70%. Simulation studies with the proposed design showed that a total of 42 subjects controls the type I error rate at the desired level 0.20 and yields a smaller average sample size and trial duration compared to a conventional design. CONCLUSIONS: Designs in rare diseases require special considerations; this is especially true for this childhood disease, which is both uncommon and acute. This design has incorporated expert consensus to establish the criteria for success, formal monitoring rules for safety, and early stopping rules.
Authors: Maja Steinlin; Sandra Bigi; Belinda Stojanovski; Jay Gajera; Maria Regényi; Marwan El-Koussy; Mark T Mackay Journal: Stroke Date: 2017-07-21 Impact factor: 7.914
Authors: Frank Miller; Sarah Zohar; Nigel Stallard; Jason Madan; Martin Posch; Siew Wan Hee; Michael Pearce; Mårten Vågerö; Simon Day Journal: Pharm Stat Date: 2018-01-10 Impact factor: 1.894
Authors: Heather J Fullerton; Nicholas Stence; Nancy K Hills; Bin Jiang; Catherine Amlie-Lefond; Timothy J Bernard; Neil R Friedman; Rebecca Ichord; Mark T Mackay; Mubeen F Rafay; Stéphane Chabrier; Maja Steinlin; Mitchell S V Elkind; Gabrielle A deVeber; Max Wintermark Journal: Stroke Date: 2018-11 Impact factor: 7.914
Authors: Peter B Sporns; Heather J Fullerton; Sarah Lee; Helen Kim; Warren D Lo; Mark T Mackay; Moritz Wildgruber Journal: Nat Rev Dis Primers Date: 2022-02-24 Impact factor: 52.329
Authors: Kelley M Kidwell; Satrajit Roychoudhury; Barbara Wendelberger; John Scott; Tara Moroz; Shaoming Yin; Madhurima Majumder; John Zhong; Raymond A Huml; Veronica Miller Journal: Orphanet J Rare Dis Date: 2022-05-07 Impact factor: 4.303